The future of heart disease treatment may change after a study found that a common post-heart attack medication might not be ...

A major international study is forcing doctors to take a second look at one of the world’s most common heart treatments.

A major international study suggests beta blockers may not benefit many patients recovering from uncomplicated heart attacks ...

Emerging details follow a May 12 report affecting more than 17,000 bottles of a commonly prescribed blood pressure drug.

A massive international study could upend 40 years of heart attack treatment. Researchers found that beta blockers—routinely prescribed after uncomplicated heart attacks—offered no real benefit for ...

Heart disease is the leading cause of death in the U-S. But even with all the information available, some people wonder which drugs they should take -- and who really needs them. Experts agree that ...

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

A huge international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart ...

AS drug shortages have reached a record high in England, there are a handful of medications that are particularly at risk of facing supply issues – from certain beta-blockers to ...

(Reuters) - Bayer will move a heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular treatments after the experimental medicine showed a "striking" reduction ...

Research shows semaglutide — commonly sold as Ozempic or Wegovy — can improve kidney function and survival rates for people ...